Literature DB >> 1689102

Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders.

H Takahashi1, W Tatewaki, K Wada, M Hanano, A Shibata.   

Abstract

In order to assess the thrombin and plasmin generation in vivo in disseminated intravascular coagulation (DIC), plasma levels of thrombin-antithrombin III (ATIII) complex (TAT) and plasmin-alpha 2-antiplasmin (a2AP) complex (PAP) were measured together with standard coagulation and fibrinolytic parameters in 80 patients with DIC. Both TAT and PAP were markedly elevated in patients with DIC. When plotted by the underlying disease categories, differences in the magnitude of the elevations of these complexes were recognized among groups. Patients with acute promyelocytic leukemia (APL) had the highest PAP, the lowest TAT/PAP ratio, low a2AP, and low fibrinogen, indicating that the most excessive fibrinolysis can occur in APL. Similar profiles, although less marked, were observed in patients with other leukemias and vascular diseases. Patients with sepsis showed the highest TAT/PAP ratio and the lowest PAP with no decrease in a2AP or fibrinogen, demonstrating a relatively impaired fibrinolysis. Patients with cancer had a relatively high TAT and high TAT/PAP ratio. In addition, both TAT and PAP were markedly elevated in patients with shock. From these, it was suggested that, although laboratory manifestations in DIC are extremely variable from patient to patient, underlying disorders are, at least in part, responsible for the observed variations. Recognition of this variable activation of coagulation and fibrinolysis would be helpful for the proper management of patients with DIC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689102     DOI: 10.1002/ajh.2830330204

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Statins reduce extensive aortic atheromas in patients with abdominal aortic aneurysms.

Authors:  Masaru Nemoto; Katsuyuki Hoshina; Toshio Takayama; Sumio Miura; Tatsu Nakazawa; Masaaki Kato; Kunihiro Shigematsu; Tetsuro Miyata; Toshiaki Watanabe
Journal:  Ann Vasc Dis       Date:  2013-11-15

Review 2.  Acute promyelocytic leukaemia in the all trans retinoic acid era.

Authors:  T G DeLoughery; S H Goodnight
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

3.  Identifying blood biomarkers and physiological processes that distinguish humans with superior performance under psychological stress.

Authors:  Amanda M Cooksey; Nausheen Momen; Russell Stocker; Shane C Burgess
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

Review 4.  Coagulation disorders in septic shock.

Authors:  L G Thijs; J P de Boer; M C de Groot; C E Hack
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

5.  Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1.

Authors:  Chien-Chung Yang; Li-Der Hsiao; Chuen-Mao Yang; Chih-Chung Lin
Journal:  Mol Neurobiol       Date:  2016-05-16       Impact factor: 5.590

Review 6.  Hemostatic alterations in cancer patients.

Authors:  F R Rickles; M Levine; R L Edwards
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 7.  Classifying types of disseminated intravascular coagulation: clinical and animal models.

Authors:  Hidesaku Asakura
Journal:  J Intensive Care       Date:  2014-03-06

Review 8.  Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis.

Authors:  Hidesaku Asakura; Hoyu Takahashi; Toshimasa Uchiyama; Yutaka Eguchi; Kohji Okamoto; Kazuo Kawasugi; Seiji Madoiwa; Hideo Wada
Journal:  Thromb J       Date:  2016-09-28

Review 9.  Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm.

Authors:  Shinya Yamada; Hidesaku Asakura
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.